Related Experiment Video
Updated: Apr 23, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.7K
Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis
Dimitrios Alexopoulos1, Ioanna Xanthopoulou1, Robert F Storey2
1Patras University Hospital, Patras, Greece.
American Heart Journal
|September 29, 2014
Summary
Platelet reactivity (PR) during ticagrelor maintenance dose is influenced by age, BMI, and smoking. Diabetes and older age correlate with lower PR, impacting treatment effectiveness.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Platelet reactivity (PR) during ticagrelor maintenance dose (MD) is not well understood.
- Identifying factors influencing PR is crucial for optimizing ticagrelor therapy.
Purpose of the Study:
- To investigate factors affecting platelet reactivity (PR) during chronic ticagrelor maintenance dose (MD).
Main Methods:
- Individual participant data meta-analysis of 445 patients from 8 studies.
- Platelet reactivity assessed using VerifyNow P2Y12 assay during ticagrelor 90 mg twice a day MD.
- Analysis focused on factors influencing PR and probability of low PR (LPR).
Main Results:
- Platelet reactivity (PR) during ticagrelor MD was generally low, with no high PR observed.
- Increased age, higher BMI, and current smoking were associated with higher PR.
- Diabetes mellitus and age >70 years were linked to a lower probability of low PR (LPR).
Conclusions:
- Age, BMI, and smoking status significantly impact PR during ticagrelor MD.
- Diabetes and advanced age are associated with a reduced likelihood of achieving low PR.
- Further research is needed to determine the clinical significance of these PR variations.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:22Formation of the Platelet Plug
6.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.0K